Jefferies Group LLC downgraded shares of Merck & Co., Inc. (NYSE:MRK) from a hold rating to an underperform rating in a report published on Wednesday. Jefferies Group also issued estimates for Merck & Co.’s FY2017 earnings at $3.97 EPS, FY2018 earnings at $4.16 EPS, FY2019 earnings at $4.16 EPS, FY2020 earnings at $4.38 EPS and FY2021 earnings at $4.74 EPS.
Several other equities research analysts also recently commented on MRK. UBS AG dropped their target price on Merck & Co. from $72.00 to $67.00 and set a buy rating on the stock in a report on Monday, October 30th. J P Morgan Chase & Co set a $70.00 target price on Merck & Co. and gave the stock a buy rating in a report on Sunday, October 29th. BMO Capital Markets set a $68.00 target price on Merck & Co. and gave the stock a buy rating in a report on Monday, October 30th. HSBC Holdings plc raised Merck & Co. from a reduce rating to a hold rating in a report on Wednesday, August 9th. Finally, Barclays PLC downgraded Merck & Co. from an overweight rating to an equal weight rating and dropped their target price for the stock from $72.00 to $62.00 in a report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $67.07.
Shares of Merck & Co. (MRK) opened at $56.06 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.21 and a current ratio of 1.50. Merck & Co. has a 1 year low of $54.41 and a 1 year high of $66.80. The firm has a market capitalization of $153,333.30, a P/E ratio of 14.41, a P/E/G ratio of 2.41 and a beta of 0.78.
Merck & Co. (NYSE:MRK) last released its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same quarter in the prior year, the firm earned $1.07 earnings per share. The company’s revenue for the quarter was down 2.0% compared to the same quarter last year. research analysts predict that Merck & Co. will post 3.95 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of MRK. Headinvest LLC increased its position in Merck & Co. by 2.2% during the first quarter. Headinvest LLC now owns 26,530 shares of the company’s stock valued at $1,686,000 after acquiring an additional 560 shares during the last quarter. Sit Investment Associates Inc. increased its position in Merck & Co. by 3.1% in the first quarter. Sit Investment Associates Inc. now owns 409,453 shares of the company’s stock worth $26,017,000 after buying an additional 12,350 shares in the last quarter. NBT Bank N A NY increased its position in Merck & Co. by 0.4% in the first quarter. NBT Bank N A NY now owns 78,167 shares of the company’s stock worth $4,967,000 after buying an additional 323 shares in the last quarter. Alexandria Capital LLC increased its position in Merck & Co. by 0.6% in the first quarter. Alexandria Capital LLC now owns 10,106 shares of the company’s stock worth $642,000 after buying an additional 58 shares in the last quarter. Finally, First Quadrant L P CA increased its position in Merck & Co. by 92.8% in the first quarter. First Quadrant L P CA now owns 428,531 shares of the company’s stock worth $27,229,000 after buying an additional 206,301 shares in the last quarter. Institutional investors own 72.86% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
What are top analysts saying about Merck & Co. Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Co. Inc. and related companies.